Trial Profile
CD20-Immunotargeting in Metastatic Melanoma Patients- A Prospective, Open Label, Sequential Pilot Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Therapeutic Use
- 05 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Jun 2011 New source identified and integrated (European Clinical Trials Database record EudraCT2010-023277-19).
- 20 Jun 2011 New trial record